Extending advertisement curbs on prescription drugs to retailers and distributors is a necessary but insufficient step against self-medication and antimicrobial resistance. Discuss.

The Health Ministry's draft amendment to the Drugs Rules, 1945 (Gazette, 28 September 2026) extends the ban on advertising Schedule H, H1 and X drugs without Central sanction to retailers, wholesalers and distributors [1]. It closes a real gap, but it targets promotion, not the point where antibiotics are actually misused.

Why the step is necessary

• Closes regulatory arbitrage: Since 2015, manufacturers have needed the Centre's prior sanction to advertise prescription drugs [2]. Sellers were outside this rule, so the same drug could be pushed through the supply chain [1].
• Expert-backed: It follows the recommendation of the 93rd DTAB meeting [1].
• Public-health logic: Schedule H and H1 include common antibiotics. Promotion at retail level encourages buyers to ask for drugs by name, which feeds AMR.
• Constitutionally defensible: Commercial speech under Art. 19(1)(a) can be reasonably restricted when the aim is to protect health.

Why it is insufficient

• The counter, not the ad, is the problem: The draft does nothing about chemists who sell antibiotics without a prescription. That is the main route to self-medication.
• Split enforcement: The Centre sanctions ads, but State drug controllers license and inspect shops [2]. Inspection capacity at the counter does not grow.
• Unlicensed promoters escape: The rule binds only licence-holders [1]. Influencers and agencies fall back on the DMR Act, 1954, which catches only false or misleading claims [3].
• Weak deterrence: The DMR Act allows only up to six months' jail for a first offence [3]. The Supreme Court had to step in directly in the Patanjali misleading-ads case.
• Digital monitoring gap: Existing mechanisms against misleading ads were built mainly around print and TV complaints [4].

Way forward

• Define "advertisement" to cover app banners and paid influencer content, and hold the paying firm liable.
• Enforce prescription checks at sale using e-prescriptions and audits, and scale up the Red Line awareness campaign.
• Raise DMR Act penalties, and share Central sanction data with State controllers.

Overall, the draft closes the advertising loophole but leaves the over-the-counter selling route open. If it is paired with counter-level enforcement, stronger penalties and digital oversight under the National Action Plan on AMR, it can become a real shield for the right to health under Art. 21 and SDG 3.